Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chinese Regulators Provide Fast-track Review Status For Lotus On Modified Version Of AstraZeneca's Bambec

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Lotus Pharmaceuticals, a Beijing-based drug maker and distributor of Western medicines, announced April 29 that the company had received clinical trial approval for its innovative anti-asthma drug R-Bambuterol Hydrochloride (laevo-bambuterol) from China's State FDA

You may also be interested in...



Asia Respiratory Group Launches Online Resource For Doctors To Treat Growing Asthma

SINGAPORE - The General Practitioner Asia Pacific Respiratory Board has launched a new website for doctors across the region to improve primary care in terms of respiratory health

Asia Respiratory Group Launches Online Resource For Doctors To Treat Growing Asthma

SINGAPORE - The General Practitioner Asia Pacific Respiratory Board has launched a new website for doctors across the region to improve primary care in terms of respiratory health

China Issues Fast-Track Registration Procedure For Drugs To Balance Innovation And Risk: SFDA Press Conference

SHANGHAI - China's State FDA issued regulations on a special approval procedure to accelerate the approval process for new drug applications, effective Jan. 7

Related Content

UsernamePublicRestriction

Register

WI964856

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel